Rosuvastatin intermediate R-2 is an important intermediate of Rosuvastatin.
6-[(1E)-2-[4-(4-fluorophenyl)-6-isopropyl -2-[methyl (methanesulfonyl) amino]-5-pyrimidine] vinyl]-2, 2-dimethyl -1,3-dioxane -4-butyl acetate is an advanced intermediate of rosuvastatin calcium. Rosuvastatin calcium was developed and screened by Japan's Shiano Pharmaceutical Co., Ltd. in the late 1980 s. After that, British AstraZeneca companies developed it again in the world except Japan and other East Asian countries. Listing time: February 2003, listed in China in 2006
